Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Effective Lentiviral Gene Therapy for X-linked Chronic Granulomatous Disease

PROVIDER: PRJNA527850 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8746810_1.fastq.gz	Fastqsanger.gz
	SRR8746810_2.fastq.gz	Fastqsanger.gz
	SRR8746820_1.fastq.gz	Fastqsanger.gz
	SRR8746820_2.fastq.gz	Fastqsanger.gz
	SRR8746830_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1344

Similar Datasets

Affymetrix SNP array data for Genomic Instability and Myelodysplasia with Monosomy 7

Project description:Gene modified autologous hematopoietic stem cells (HSC) can provide significant clinical benefits to patients suffering from X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency characterized by recurrent, often life threatening bacterial and fungal infections. Here we report on the molecular and cellular events observed in two patients treated by gene therapy in 2004. After the initial resolution of bacterial and fungal infections, both patients exhibited silencing of transgene expression due to methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional activation of EVI1. One patient died from overwhelming sepsis 27 months after gene therapy, whereas a second patient underwent an allogeneic HSC transplantation. Our data shows that forced overexpression of MDS1/EVI1 or EVI1 in human cells disrupts normal centrosome duplication, linking MDS1/EVI1 activation to the development of genomic instability, monosomy 7 and clonal progression towards myelodysplasia. Genomic copy number alterations were detected by analyzing the fluorescence signal intensities of each SNP on the GeneChip Human Mapping 100K array st (Affymetrix, Santa Clara, Ca) with the Copy Number Analyzer for Affymetrix GeneChip 100K arrays (CNAT) version 2.0. The log2 ratio of each SNP, the local averaged log2 signal ratio (averaged for 10 SNPs) and the inferred chromosome copy number according to the Hidden Markov Model (HMM) were calculated. Copy number analysis of Affymetrix 100K SNP arrays was performed for one young adult with the X-linked chronic granulomatous disease (X-CGD)

2010-01-12 | E-GEOD-19523 | biostudies-arrayexpress

X-CGD iPS cells before and after genome editing by designer nucleases

Project description:X-CGD (X-linked chronic granulomatous disease) patient derived CD34+ cells were reprogrammed into two X-CGD iPSC clones (7 and 25) and subsequently corrected using ZFN (clone 7) and TALEN (clone 25) by integrating a therapeutic gp91phox expression cassette into the AAVS1 "safe harbor" locus

2015-02-28 | GSE66337 | GEO

Homo sapiens

Project description:NIH/NIAID Chronic Granulomatous Disease Neutrophils

| PRJNA87967 | ENA

X-CGD iPS cells before and after genome editing by designer nucleases

2015-02-28 | E-GEOD-66337 | biostudies-arrayexpress

Affymetrix SNP array data for Genomic Instability and Myelodysplasia with Monosomy 7

2010-01-13 | GSE19523 | GEO

Homo sapiens

Project description:Genome wide gene expression analysis of chronic granulomatous disease patients

| PRJNA192662 | ENA

Granulibacter bethesdensis CGDNIH1

Project description:Isolated from a patient with chronic granulomatous disease

| PRJNA17111 | ENA

Francisella philomiragia subsp. philomiragia ATCC 25017

Project description:Causes bacteremia in patients with chronic granulomatous disease

| PRJNA27853 | ENA

Proteomic analysis of bronchoalveolar lavage fluid from patients with active TB and at the end of treatment

Project description:Tuberculosis (TB) is a chronic granulomatous disease caused by the pathogen Mycobacterium tuberculosis. The success of M. tuberculosis can be attributed to its ability to evade protective host immune responses and its recalcitrance to antimicrobial chemotherapy. Detailed understanding of protective host immune response to TB is still lacking and there are limited reports that characterize host responses to TB at the site of disease. Furthermore, although cure of the majority of patients treated with the standard 6-month multidrug regimen indicates that treatment is highly effective, approximately 4-10% of clinically cured patients will develop recurrent disease within the first 12 months after completing therapy. We therefore analyzed BALF supernatant proteomes from pulmonary TB patients and patients at the end of standard anti-TB treatment to gain a better understanding of the host response at the site of disease. This would not only aid our understanding of localised host responses during TB disease, but could allow us to identify protein signatures associated with active TB disease or clinical cure.

2021-11-03 | PXD018907 | Pride

Project description:Preclinical Development of a Lentiviral Vector for Gene Therapy of X-linked Severe Combined Immunodeficiency

| PRJNA438481 | ENA